Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Recent advances in cancer genomics and targeted therapies have substantially changed the management of lung cancer, but like many new medical technologies, there is a concern these new methods, which include biomarker testing, will not be used equally throughout the health care system and worsen disparities that may already be entrenched.
PowerPoint Presentation ACKNOWLEDGEMENTS AND DISCLOSURES: The authors would like to thank the patients who were involved in this research for their thoughtful and considerate responses to the survey questions. Professional medical writing and editorial assistance were provided by Greg Salinas, PhD, of CE Outcomes, LLC. This study was supported by a joint grant from Foundation …
Presented at the IASLC 2021 World Conference on Lung Cancer, September 8-14, 2021
With total spending on U.S. cancer care projected to rise 34 percent from 2015-2030 to $245 billion, biosimilars can play a role in helping reduce those costs. Learn how Biden’s executive order on promoting competition in the American economy will require the FDA's biosimilars approval framework to be clearer and easier to follow.
At Northwest Medical Specialties, we, too, face challenges from staff stress and exhaustion. To address and overcome these challenges, our management team has made it a priority to bolster the resiliency of our staff.
The purpose of this study was to assess patient, disease, and medication-related factors that affect the rate of unplanned readmissions before next chemotherapy cycle or within 30 days since last chemotherapy admission in patients with hematologic malignancies.
16 accc-cancer.org | Vol. 36, No. 5, 2021 | OI M aryland Oncology Hematology is one of the largest independent oncology practices in Maryland, serving patients in the state and the metro Washington, D.C., area. With 14 physician- owned locations, Maryland Oncology Hematology provides its communities value-based and integrated cancer care close to home through its dedicated staff and membership …
Thirty-six medical oncologists, practicing at 21 sites in groups that ranged in size between 1 and 8, were paid according to 14 variations of 9 individual practice plans. We felt that the window of opportunity was optimal to convert individual sites into a functionally cohesive and interactive group using financial goals and rewards to encourage behavioral changes.
A curbside clinic offers patients another option for accessing cancer care | 44 Tailoring distress screening to meet the needs of specific patient populations | 30 This publication is a benefit of membership Association of Community Cancer Centers Vol. 36 | No. 5 | 2021 Creating an oncology practice plan that can change with the times | 24 ISSUES ONCOLOGY A digital screening …
14 accc-cancer.org | Vol. 36, No. 5, 2021 | OI Approved Drugs • On June 16, the U.S. Food and Drug Administration (FDA) approved Ayvakit™ (avapritinib) (Blueprint Medicines, blueprintmedicines.com) for adult patients with advanced systemic mastocytosis (SM), including patients with aggressive SM, SM with an associ- ated hematological neoplasm, and mast cell leukemia. • On July …
In an interview with Oncology Issues, Dr. Weiss shares why she believes this work is important in all levels of healthcare—from the clinic to the boardroom.
Because interdisciplinary teams become specialists in treating certain disease sites, it is important to develop distress screening guidelines that best serve specific patient populations and their treatment.
A curbside clinic offers patients another option for accessing cancer care | 44 Tailoring distress screening to meet the needs of specific patient populations | 30 This publication is a benefit of membership Association of Community Cancer Centers Vol. 36 | No. 5 | 2021 Creating an oncology practice plan that can change with the times | 24 ISSUES ONCOLOGY A digital screening …
fast facts BLOG more online @ accc-cancer.org PODCAST RESOURCE WEBINAR Cancer Care’s Road to Recovery from the Global Pandemic Debra Patt, MD, PhD, MBA, FASCO, executive vice president, Public Policy and Strategic Initiatives at Texas Oncology, talks to ACCCBuzz about how delays in cancer screening and treatment during COVID-19 are translating into cancer mortality. But the …
OI | Vol. 36, No. 5, 2021 | accc-cancer.org 75 action ACCC Welcomes Its Newest Members St. Luke’s University Health Network, Cancer Center Easton, Pa. Delegate Rep: Jesse Keiper, BS Website: slhn.org Texas Oncology Austin, Tex. Delegate Rep: Tammy Sayers Website: texasoncology.com Tulane Medical Center Tulane Cancer Center New Orleans, La. Delegate Rep: Laura Godel, PMP Website: …
Because oral anti-cancer agents are most often administered outside of the clinic setting, it takes a multidisciplinary team to successfully manage these patients and their treatments.
At Middlesex Health Cancer Center, we knew we could not let another year pass without an in-person celebration of all that our survivors and staff have endured. We were determined to bring people together again in a safe way.
Oncology Issues talked with Karen Clark, MS, manager of Supportive Care Programs, City of Hope, about the process, how the digital distress screening tool is currently integrated into the electronic health record (EHR), and next steps.
There remains an overarching need to identify and provide guidance on key issues related to the optimal care of patients with NSCLC across different community cancer programs/settings in the U.S. To address this need, a multiphase project was implemented by ACCC and its partner organizations, with the main goal being to support the optimization of care for patients diagnosed with stage III and IV …
Many times, being present, allowing the grief, and letting our patients know they aren’t alone is the only “treatment” we have. So, what sustains us? How do we do this every day?